Warnings and Precautions
Embryofetal Risk Females of childbearing potential should be warned of
the potential risk and use adequate birth-control measures when ARAZLO Lotion is used. A
negative result for pregnancy should be obtained within 2 weeks prior to ARAZLO Lotion
therapy. ARAZLO Lotion therapy should begin during a menstrual period.
Skin Irritation Patients using ARAZLO Lotion may experience application
site pain, dryness, exfoliation, erythema, and pruritus. Depending upon severity of
these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of
the application of ARAZLO Lotion, or discontinue use. Therapy can be resumed, or the
frequency of application can be increased, as the patient becomes able to tolerate
treatment. Avoid application of ARAZLO Lotion to eczematous or sunburned skin.
Ultraviolet Light and Environmental Exposure Minimize unprotected
exposure to ultraviolet light, including sunlight and sunlamps, during the use of ARAZLO
Lotion. Warn patients who normally experience high levels of sun exposure and those with
inherent sensitivity to sun to exercise caution. Use sunscreen products and protective
clothing over treated areas when sun exposure cannot be avoided. ARAZLO Lotion should be
administered with caution if the patient is also taking drugs known to be
photosensitizers (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines,
sulfonamides) because of the increased possibility of augmented photosensitivity.
Weather extremes, such as wind or cold, may be more irritating to patients using ARAZLO
Adverse Reactions The most common adverse reactions (in ≥1% of
patients and greater than vehicle) were: pain, dryness, exfoliation, erythema, and
pruritus (all at application site).
To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or
FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please click here for full Prescribing Information.
References: 1. ARAZLO Lotion [prescribing information]. Bridgewater, NJ.
Bausch Health US, LLC. 2. Tanghetti EA, Kircik LH, Green LJ, et al. A
phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to
compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1%
cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol.
2019;18(6):542-548. 3. Food and Drug Administration. Orange Book:
Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm.
Accessed October 10, 2019. 4. Data on file.